CHINARES PHARMA 's DC7001A Capsules Approved by US FDA for Clinical Trials

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CHINARES PHARMA (03320.HK) -0.005 (-0.114%) Short selling $1.39M; Ratio 26.358% announced that its subsidiary Shuanghe Runchuang recently received notification from the US FDA approving clinical trials for DC7001A capsules, which are intended for the treatment of systemic lupus erythematosus.

In May 2026, Shuanghe Runchuang submitted a clinical trial application for DC7001A capsules to China's National Medical Products Administration, and received the Drug Clinical Trial Approval Notice issued by the regulator in August. The drug is registered as a Category 1 innovative chemical drug and is intended for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-10-12 12:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.